Canna Law Blog
NOVEMBER 27, 2021
In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction. Compass Pathways Releases Phase 2B Trial Results.
The Cannigma
DECEMBER 12, 2022
What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. At most, a mood boost should be all that is felt, and if any visual or auditory effects are noticeable then the dose is not, by definition, a microdose. Everyone is different.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
NOVEMBER 15, 2021
Microdose hosted its annual psychedelics conference in Miami last week (appropriately titled “Wonderland”). This is a topic we have covered regularly on the Canna Law Blog, most recently by Mason Marks , here. We were there, meeting industry insiders and clients, and keeping on the cutting edge of the psychedelics space.
The Cannigma
JUNE 24, 2021
These natural alternatives may also be effective as part of a daily “microdosing” regiment. While more human clinical trials are needed, the current evidence suggests there may be potential therapeutic benefits for the following ailments: Chronic pain — the most common reason people turn to medical cannabis in the United States today.
Cannabis Law Report
NOVEMBER 24, 2019
Dr. Johnson recently spoke about microdosing and its affects on creativity. Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. Participate in Our Studies. ANOREXIA NERVOSA. ALZHEIMER’S DISEASE.
Cannabis Law Report
SEPTEMBER 10, 2019
” Here’s some of the topics covered in their latest newsletter. Forbes reported on Hopkins researchers’ recommendation that, if psilocybin should clear Phase III clinical trials, the FDA should reclassify it from a Schedule I to a Schedule IV drug. Psychedelic Research News.
CannaMD
OCTOBER 7, 2019
As the study authors explain: Our theory suggests that the psychoactive effects of CB1 receptor stimulation with THC may be a necessary accompaniment to cannabis-induced weight loss, because down-regulation of CB1 receptors is required for reduced BMI, and it is not yet clear whether microdosing will cause down-regulation.
Expert insights. Personalized for you.
88 
Let's personalize your content